Hologic, Inc. (HOLX) Shares Sold by Strategic Global Advisors LLC
Strategic Global Advisors LLC lowered its holdings in Hologic, Inc. (NASDAQ:HOLX) by 10.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 81,803 shares of the medical equipment provider’s stock after selling 9,390 shares during the period. Hologic comprises 1.4% of Strategic Global Advisors LLC’s holdings, making the stock its 14th largest position. Strategic Global Advisors LLC’s holdings in Hologic were worth $3,712,000 as of its most recent SEC filing.
A number of other hedge funds have also bought and sold shares of the business. Stratos Wealth Partners LTD. boosted its position in Hologic by 0.6% in the second quarter. Stratos Wealth Partners LTD. now owns 4,954 shares of the medical equipment provider’s stock worth $225,000 after purchasing an additional 30 shares during the last quarter. Cleararc Capital Inc. raised its stake in shares of Hologic by 1.1% in the first quarter. Cleararc Capital Inc. now owns 6,843 shares of the medical equipment provider’s stock valued at $291,000 after buying an additional 77 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its stake in shares of Hologic by 0.4% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 20,803 shares of the medical equipment provider’s stock valued at $944,000 after buying an additional 85 shares during the period. Compton Capital Management Inc. RI raised its stake in shares of Hologic by 0.6% in the first quarter. Compton Capital Management Inc. RI now owns 16,810 shares of the medical equipment provider’s stock valued at $715,000 after buying an additional 100 shares during the period. Finally, Symphony Asset Management LLC raised its stake in shares of Hologic by 0.4% in the second quarter. Symphony Asset Management LLC now owns 28,005 shares of the medical equipment provider’s stock valued at $1,271,000 after buying an additional 108 shares during the period. 96.39% of the stock is currently owned by institutional investors and hedge funds.
In related news, Director Elaine Ullian sold 8,849 shares of Hologic stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $45.28, for a total transaction of $400,682.72. Following the transaction, the director now directly owns 23,810 shares in the company, valued at $1,078,116.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Lawrence M. Levy sold 7,139 shares of Hologic stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $39.04, for a total value of $278,706.56. The disclosure for this sale can be found here. Insiders have sold 27,594 shares of company stock worth $1,168,871 over the last quarter. 0.79% of the stock is owned by company insiders.
Hologic, Inc. (HOLX) traded down 0.05% during mid-day trading on Friday, hitting $37.72. The company had a trading volume of 3,344,455 shares. The company has a market capitalization of $10.58 billion, a price-to-earnings ratio of 14.05 and a beta of 0.92. Hologic, Inc. has a 52 week low of $35.15 and a 52 week high of $46.80. The firm’s 50 day moving average is $38.90 and its 200 day moving average is $42.58.
Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.49 by $0.01. The company had revenue of $806.10 million for the quarter, compared to the consensus estimate of $799.70 million. Hologic had a return on equity of 23.18% and a net margin of 25.65%. Hologic’s quarterly revenue was up 12.4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.51 earnings per share. On average, equities research analysts predict that Hologic, Inc. will post $2.01 EPS for the current year.
Several analysts have issued reports on HOLX shares. Zacks Investment Research lowered Hologic from a “hold” rating to a “sell” rating in a research note on Wednesday, July 12th. Royal Bank Of Canada lowered their target price on Hologic from $50.00 to $45.00 and set a “sector perform” rating on the stock in a research note on Thursday, August 3rd. Deutsche Bank AG lowered their target price on Hologic from $51.00 to $49.00 and set a “buy” rating on the stock in a research note on Thursday, August 3rd. Barclays PLC lowered their target price on Hologic from $53.00 to $51.00 and set an “overweight” rating on the stock in a research note on Thursday, August 3rd. Finally, Piper Jaffray Companies restated a “buy” rating and issued a $51.00 target price on shares of Hologic in a research note on Friday, July 14th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $48.64.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).
Receive News & Stock Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related stocks with our FREE daily email newsletter.